Skip to main content
TipRanks
Go Ultimate75% OFF

Scancell Holdings (SCNLF) AI Stock Analysis

19 Followers
SCNLF

Scancell Holdings

(Other OTC:SCNLF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Proprietary Immunotherapy PlatformsProprietary platforms can provide a differentiated foundation for developing multiple immunotherapy candidates rather than relying on a single asset. If translated successfully into clinical products, this technology base could support longer-term pipeline expansion across the company’s therapeutic programs.
Negative Factors
Persistent Operating LossesLarge and persistent operating losses show that the business has not yet converted its research platform and pipeline into profitable operations. Continued losses can consume resources needed for development and increase reliance on future financing before commercial earnings emerge.

Scancell Holdings (SCNLF) vs. SPDR S&P 500 ETF (SPY)

-25%0%25%50%75%100%125%150%SCNLF-22.96%SPY+4.27%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$95.77M
Dividend Yield
―
Average Volume (3M)
1,702
Price to Earnings (P/E)
-4.5
Beta (1Y)
0.47
Revenue Growth
-100.00%
EPS Growth
-35.56%
Country
US
Employees
55
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Scancell Holdings Business Overview & Revenue Model

Company Description

Scancell Holdings plc is a clinical-stage biopharmaceutical firm focused on discovering and developing innovative vaccine and antibody treatments. Its mission is to address significant unmet medical needs in both cancer and infectious diseases. The c...

Scancell Holdings Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SCNLF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GB:4BBGB:4BB52NeutralGBP 100.70M-4.53-316.73%―-56.10%-16.77%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:SARGB:SAR47NeutralGBP 23.75M-6.04-188.01%――28.78%
GB:POLBGB:POLB42NeutralGBP 46.95M-7.88-71.28%――31.58%
GB:OBIGB:OBI38UnderperformGBP 54.55M-2.40-9999.00%―26.99%4.36%
GB:ARECGB:AREC33UnderperformGBP 32.39M143.003.75%―――

* Healthcare Sector Average

Performance Comparison

0%50%100%150%SCNLFGB:SARGB:4BBGB:POLBGB:ARECGB:OBIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SCNLF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SCNLFScancell Holdings1.04-0.31-22.96%
GB:SARSareum Holdings14.501.5011.54%
GB:4BB4basebio UK Societas525.00-187.50-26.32%
GB:POLBPoolbeg Pharma Ltd.6.152.6073.24%
GB:ARECArecor Therapeutics PLC71.50-2.50-3.38%
GB:OBIOndine Biomedical, Inc.8.25-3.00-26.67%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.